CliffBio
small molecule

TYBOST

COBICISTAT

Loss of exclusivityApril 2033latest FDA-listed patent expiry
CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameTYBOST
Active ingredientCOBICISTAT
Strength150MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
10039718*PEDApril 2033—
10039718October 2032product
8148374*PEDMarch 2030—
8148374September 2029substance, product

Regulatory exclusivity

CodeExpires
NPPJune 2028
ODE-260August 2026

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.